Furihata et al., Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study

Supplementary Material:

Legends to Supplementary Figures:

Figure S1: Study design.

Figure S2: Participant disposition.
Supplementary Figure S1:

Step 1 (1 mg/kg, Japanese) on Day 29

Step 2 (3 mg/kg, Japanese) on Day 29

Step 3-1 (10 mg/kg, Japanese) on Day 29

Step 3-2 (10 mg/kg, White) on Day 29

Step 4 (20 mg/kg, Japanese)

Step 1: 2 participants
NPC-21: n = 1; Placebo, n = 1
Day 8

Step 1: 6 participants
NPC-21: n = 5; Placebo, n = 1
Supplementary Figure S2:

List of participants for the study:

 Participants randomized N = 40

- NPC-21, 1 mg/kg n = 6
- NPC-21, 3 mg/kg n = 6
- NPC-21, 10 mg/kg (Japanese) n = 6
- NPC-21, 10 mg/kg (White) n = 6
- NPC-21, 20 mg/kg n = 6
- NPC-21 placebo n = 10

Participants treated N = 40

- NPC-21, 1 mg/kg n = 6
- NPC-21, 3 mg/kg n = 6
- NPC-21, 10 mg/kg (Japanese) n = 6
- NPC-21, 10 mg/kg (White) n = 6
- NPC-21, 20 mg/kg n = 6
- NPC-21 placebo n = 10

Completed study N = 40

- NPC-21, 1 mg/kg n = 6
- NPC-21, 3 mg/kg n = 6
- NPC-21, 10 mg/kg (Japanese) n = 6
- NPC-21, 10 mg/kg (White) n = 6
- NPC-21, 20 mg/kg n = 6
- NPC-21 placebo n = 10